JP2023549469A - 新規ｃｘｃｒ４標的化合物 - Google Patents

新規ｃｘｃｒ４標的化合物 Download PDF

Info

Publication number
JP2023549469A
JP2023549469A JP2023524397A JP2023524397A JP2023549469A JP 2023549469 A JP2023549469 A JP 2023549469A JP 2023524397 A JP2023524397 A JP 2023524397A JP 2023524397 A JP2023524397 A JP 2023524397A JP 2023549469 A JP2023549469 A JP 2023549469A
Authority
JP
Japan
Prior art keywords
residue
lys
ipr
forms
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549469A5 (https=
Inventor
ベナール，フランソワ
リン，クオ－シュヤン
ジャン，ジョンシン
クォン，ダニエル
ペラン，ダヴィド
トドロヴィチ，ミハイロ
ロサダ，ジェローム
リー リィ，リー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Provincial Health Services Authority
Original Assignee
Provincial Health Services Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provincial Health Services Authority filed Critical Provincial Health Services Authority
Publication of JP2023549469A publication Critical patent/JP2023549469A/ja
Publication of JP2023549469A5 publication Critical patent/JP2023549469A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023524397A 2020-10-21 2021-10-21 新規ｃｘｃｒ４標的化合物 Pending JP2023549469A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063094839P 2020-10-21 2020-10-21
US63/094,839 2020-10-21
PCT/CA2021/051486 WO2022082312A1 (en) 2020-10-21 2021-10-21 Novel cxcr4-targeting compounds

Publications (2)

Publication Number Publication Date
JP2023549469A true JP2023549469A (ja) 2023-11-27
JP2023549469A5 JP2023549469A5 (https=) 2024-10-28

Family

ID=81291055

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524397A Pending JP2023549469A (ja) 2020-10-21 2021-10-21 新規ｃｘｃｒ４標的化合物

Country Status (9)

Country Link
US (1) US20240100203A1 (https=)
EP (1) EP4232459A4 (https=)
JP (1) JP2023549469A (https=)
KR (1) KR20230092906A (https=)
CN (1) CN116457028A (https=)
AU (1) AU2021366975A1 (https=)
CA (1) CA3194483A1 (https=)
IL (1) IL301342A (https=)
WO (1) WO2022082312A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4511384A1 (en) * 2022-04-20 2025-02-26 Provincial Health Services Authority Cxcr4-targeting compounds, and methods of making and using the same
US12614326B2 (en) * 2023-05-03 2026-04-28 GE Precision Healthcare LLC Methods and systems for scatter and tailing correction
US12514939B2 (en) 2024-02-14 2026-01-06 Alpha-9 Oncology, Inc. Stable radiopharmaceutical compositions and uses thereof
WO2025171492A1 (en) * 2024-02-14 2025-08-21 Alpha-9 Oncology Inc. Stable radiopharmaceutical compositions and uses thereof
WO2025218761A1 (zh) * 2024-04-17 2025-10-23 晶核生物医药科技(上海)有限公司 环状肽类化合物、其药物组合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150689A1 (en) * 2007-05-30 2008-12-11 Eli Lilly And Company Cyclic peptide cxcr4 antagonists
WO2020009093A1 (ja) * 2018-07-03 2020-01-09 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006035705A1 (de) * 2006-08-01 2008-02-07 Robert Bosch Gmbh Kolben einer Fahrzeugbremsanlagen-Kolbenpumpe
CN113150068B (zh) * 2017-09-20 2023-04-04 尚华医药科技(江西)有限公司 一种肽类化合物、其应用及含其的组合物
US20220218852A1 (en) * 2019-04-18 2022-07-14 Provincial Health Services Authority Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150689A1 (en) * 2007-05-30 2008-12-11 Eli Lilly And Company Cyclic peptide cxcr4 antagonists
WO2020009093A1 (ja) * 2018-07-03 2020-01-09 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体

Also Published As

Publication number Publication date
US20240342321A1 (en) 2024-10-17
US20240100203A1 (en) 2024-03-28
EP4232459A4 (en) 2024-12-04
KR20230092906A (ko) 2023-06-26
CN116457028A (zh) 2023-07-18
EP4232459A1 (en) 2023-08-30
WO2022082312A1 (en) 2022-04-28
AU2021366975A1 (en) 2023-04-13
IL301342A (en) 2023-05-01
CA3194483A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
JP7659268B2 (ja) デュアルモード１８ｆ標識セラノスティック化合物及びその使用
JP2023549469A (ja) 新規ｃｘｃｒ４標的化合物
CN119431260A (zh) 靶向前列腺特异性膜抗原的放射性标记化合物
JP7541532B2 (ja) 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
AU2019273132B2 (en) Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
AU2020257786B2 (en) Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
US20250242064A1 (en) Cxcr4-targeting compounds, and methods of making and using the same
US20250195702A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
TW202541853A (zh) 增濃且安定之放射配體治療調製劑及包含彼之醫藥組成物
US12616761B2 (en) CXCR4-targeting compounds
WO2025054727A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
WO2025111712A1 (en) Gastrin-releasing peptide receptor (grpr)-targeted compounds and uses thereof
WO2025147774A1 (en) Compositions targeting bradykinin receptor b1 for medical imaging and treatment of cancer and other disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260421